摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-乙酰氧基-2-萘酚 | 61982-81-8

中文名称
1-乙酰氧基-2-萘酚
中文别名
——
英文名称
1-Acetoxy-2-hydroxynaphthalin
英文别名
1-acetoxyl-2-naphthol;Acetic acid 2-hydroxy-1-naphthyl ester;(2-hydroxynaphthalen-1-yl) acetate
1-乙酰氧基-2-萘酚化学式
CAS
61982-81-8
化学式
C12H10O3
mdl
——
分子量
202.21
InChiKey
UEPLGQIXYNRNBT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    355.4±25.0 °C(Predicted)
  • 密度:
    1.266±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    46.5
  • 氢给体数:
    1
  • 氢受体数:
    3

SDS

SDS:2d20bc6a323c7062a50d1bccd9e83970
查看

反应信息

  • 作为产物:
    描述:
    溶剂黄1461-diazo-2(1H)naphthalenone 在 palladium diacetate 作用下, 反应 1.0h, 生成 2-乙酰氧基-1-羟基萘1-乙酰氧基-2-萘酚
    参考文献:
    名称:
    Pd(II) 催化的重氮萘醌与乙酸的形式 O-H 插入反应:1,2-萘二醇衍生物的合成
    摘要:
    Pd(II) 催化的重氮萘醌与乙酸的 O-H 插入反应得到 1,2-萘二醇单乙酸酯。在卤化锂存在下,卤代萘酚...
    DOI:
    10.1246/cl.2011.1129
点击查看最新优质反应信息

文献信息

  • [EN] (3-{3-'(2,4-BIS-TRIFLUORMETHYL-BENZYL)-(5-ETHYL-PYRIMIDIN-2-YL)-AMINO!-PROPOXY}-PHENYL)-ACETIC ACID AND RELATED COMPOUNDS AS MODULATORS OF PPARS AND METHODS OF TREATING METABOLIC DISORDERS<br/>[FR] ACIDE (3-{3- (2,4-BIS-TRIFLUORMETHYL-BENZYL)-(5-ETHYL-PYRIMIDIN-2-YL)-AMINO!-PROPOXY}-PHENYL)-ACETIQUE ET COMPOSES ASSOCIES EN TANT QUE MODULATEURS DE PPAR, ET PROCEDES POUR TRAITER DES TROUBLES DU METABOLISME
    申请人:KALYPSYS INC
    公开号:WO2004093879A1
    公开(公告)日:2004-11-04
    Disclosed are compounds of formula I as modulators of peroxisome proliferator activated receptors (PPARs) for the treatment of metabolic diseases such as obesity: wherein Ar1 is selected from the group consisting of a monocyclic heteroarornatic ring structure and a bicyclic heteroaromatic ring structure; Ar2 is selected from the group consisting of a monocyclic, a bicyclic, and a tricyclic carbocyclic aryl ring structure R1 is selected from the group consisting of alkyl, optionally substituted a five-membered or six-membered heteroarylring or a six-membered aryl ring, optionally substituted R2 is selected from the group consisting of hydrogen; alkyl, optionally substituted a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, optionally substituied cyano; nitro; an amino; an amido; perhaloalkyl; and halogen; R3 is selected from the group consisting of hydrogen; alkyl, optionally substituted and B is a five-membered or six-membered heteroaryl ring, or -(CH2)j-C(O)OR4, wherein j is 0 or I 1 when Ar2 is a bicyclic or tricyclic carbocyclic ring structure and j is 1 when Ar2 is a monocyclic carbocyclic ring structure; and R4 is selected from the group consisting of hydrogen; alkyl, optionally substituted a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, optionally substituted. The obtional substituents are as defined in claim 1.
    公开了如下式化合物作为过氧化物酶增殖物激活受体(PPARs)的调节剂,用于治疗肥胖等代谢性疾病:其中Ar1选自由单环杂芳环结构和双环杂芳环结构组成的群体;Ar2选自由单环、双环和三环碳环芳基环结构组成的群体;R1选自烷基、可选择地取代的五元环或六元环杂芳基环或六元芳基环,可选择地取代;R2选自氢;烷基,可选择地取代的五元环或六元环杂芳基环或六元芳基环,可选择地取代氰基;硝基;氨基;酰胺基;全氟烷基;和卤素;R3选自氢;烷基,可选择地取代;B是五元环或六元环杂芳基环,或-(CH2)j-C(O)OR4,其中j为0或1,当Ar2为双环或三环碳环环结构时,j为1,当Ar2为单环碳环环结构时;R4选自氢;烷基,可选择地取代的五元环或六元环杂芳基环或六元芳基环,可选择地取代。可选择的取代基的定义如权利要求1所述。
  • Maruyama, Kazuhiro; Takuwa, Akio; Matsukiyo, Shigeo, Journal of the Chemical Society. Perkin transactions I, 1980, p. 1414 - 1419
    作者:Maruyama, Kazuhiro、Takuwa, Akio、Matsukiyo, Shigeo、Soga, Osamu
    DOI:——
    日期:——
  • EP1613326A1
    申请人:——
    公开号:EP1613326A1
    公开(公告)日:2006-01-11
  • (3-{3-'(2,4-BIS-TRIFLUORMETHYL-BENZYL)-(5-ETHYL-PYRIMIDIN-2-YL)-AMINO]-PROPOXY}-PHENYL)-ACETIC ACID AND RELATED COMPOUNDS AS MODULATORS OF PPARS AND METHODS OF TREATING METABOLIC DISORDERS
    申请人:Kalypsys, Inc.
    公开号:EP1613326B1
    公开(公告)日:2006-09-13
  • Aryl compounds as modulators of PPARS and methods of treating metabolic disorders
    申请人:Liu Kevin
    公开号:US20050070532A1
    公开(公告)日:2005-03-31
    Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.
查看更多